Economists polled by Reuters had expected Chinese exports denominated in the U.S. dollar to fall by 3% and imports to decline by 5.2% in September, compared to a year ago.China Economyread more
The U.S. had plans to hike duties on at least $250 billion in Chinese goods to 30% from 25% on Tuesday. Despite the partial trade deal, some banks on Sunday wrote that tariff...Marketsread more
The industry has pulled in $322 billion over the past six months, the fastest pace since the second half of 2008.Marketsread more
A technical recession occurs when there are two consecutive quarters of economic contraction.Asia Economyread more
"Deepfakes" are being used to depict people in fake videos they did not actually appear in, and can potentially affect elections, diplomacy and how markets move, experts say.Technologyread more
A spokesperson for the U.S.-backed Syrian Democratic Forces (SDF) has issued a stark warning to the international community.World Newsread more
The potential deal would shift Neumann's already diminished voting power to the Japanese conglomerate, according to the Journal.Technologyread more
U.S. President Donald Trump said that both sides reached a "very substantial phase one deal" that will address intellectual property and financial services concerns and...Asia Marketsread more
On Friday, Zedd tweeted about the ban, and CNBC verified the claim with his publicist on Saturday.China Politicsread more
Hunter's vows to forgo any foreign work follow a slew of unsubstantiated attacks by President Donald Trump accusing him of corruption.Politicsread more
Apple, the company that created the modern-day smartphone, is relying on technology customers are already extremely familiar with, like cameras, and taking a backseat when it...Technologyread more
Jim Cramer has found one speculative biopharmaceutical company that has already quadrupled and isn't done rewarding your portfolio, yet.
Receptos is a biopharmaceutical company that is focused on therapeutics for immune disorders. The stock took off in 2014, thanks to its clinical trial data for a drug called Ozanimod, which treats multiple sclerosis. Cramer sees enormous potential with this drug, which could even be worth billions.
Ozanimod is currently in Phase 3 trials as an oral treatment, and thus far, the data has indicated it is better than the competition oral treatment drug for MS.
Additionally, there are studies underway that have strong data indicating it could also treat ulcerative colitis and Crohn's disease, and in the long-term it could work for diseases like lupus or psoriasis, as well.
Could the healthy outlook translate into hefty investor profits? To find out, Cramer spoke with Receptos CEO Faheem Hasnain.
"Our efficacy data looks every bit as good, and, importantly, our safety profile seems to be a real improvement for patients with this disease," Hasnain said.
The CEO clarified that the significance of Ozanimod is that there is an unmet need for drugs to treat the disease once steroids or immune suppressants no longer work. Receptos' drug is a pill taken once daily, unlike the other options, which are given through IV or injections.
Additionally, a third of patients flare within a year of taking steroids and require more aggressive treatment. A third of patients don't even respond to biologics, and, of the ones that do, only 50 percent will have a durable response.
Hasnain thinks this speaks to the large need for patients who are living with the disease and really need new options.
"I think it is fair to say that this data is as good as it gets. Certainly as good as any of the biologics," he added.
The potential for Receptos could be huge, as there are three times as many patients living with inflammatory bowel disease than multiple sclerosis. So, if this new drug can treat ulcerative colitis, it will open the door to much wider use.
Read more from Mad Money with Jim Cramer
Cramer Remix: This one stock leading many higher
Cramer: Secret catalyst behind the housing boom
Cramer: The stock rotation ruining your portfolio
"We have been known up until this point in time as a multiple sclerosis company because of our first set of trials that we read out…What is really exciting and what's new is this data in inflammatory bowel disease, ulcerative colitis, specifically," Hasnain said.
Even Cramer thinks the pipeline holds plenty of potential for investors, saying, "This is real. This is a major drug that could have multiple indications. Receptos is a very, very exciting speculative stock."